Tonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder
November 13, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Children with Autism Spectrum Disorder are at Risk for Low Bone Density Preliminary Data Suggest that the Administration of Oxytocin May Favorably Impact Bone Formation and Strength Recent...
Tonix Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Highlights
November 09, 2023 16:15 ET
|
Tonix Pharmaceuticals Holding Corp.
Topline Results from Phase 3 Potentially NDA-Enabling Study of TNX-102 SL in Fibromyalgia Expected Late December 2023: Centrally-Acting Non-Opioid Analgesic Topline Results from Phase 2...
Tonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Congress
October 30, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital TNX-1500 is currently in Phase 1 Clinical Development Tonix is Developing TNX-1500 for...
Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models
October 18, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital TNX-1500 is Enrolling in a Phase 1 Clinical Trial Tonix is Developing TNX-1500 for Prevention...
IBA signe un contrat pour la modernisation de son premier système de protonthérapie
October 18, 2023 01:00 ET
|
IBA SA
Actualisation complète de la machine historique offrant une opportunité de solution durable Louvain-la-Neuve, Belgique, le 18 octobre 2023 - IBA (Ion Beam Applications S.A., EURONEXT), le leader...
IBA plans total system restoration on its first-ever proton therapy installation
October 18, 2023 01:00 ET
|
IBA SA
Comprehensive restoration of legacy machine offers the opportunity for sustainable solution Louvain-La-Neuve, Belgium, October 18, 2023 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader...
The Southport School & The Southport CoLAB to Host Simulcast of The Dyslexia Foundation Conference
October 02, 2023 12:15 ET
|
The Southport School Inc
SOUTHPORT, Conn., Oct. 02, 2023 (GLOBE NEWSWIRE) -- The Southport School, an independent day school for cerebrodiverse children in grades 2-8 with language-based learning differences as well as...
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer
September 21, 2023 08:00 ET
|
Replay Bio
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer Collaboration leverages JURA Bio’s T cell receptor (TCR) discovery platform...
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
September 07, 2023 07:03 ET
|
Axsome Therapeutics, Inc.
Data presentations explore effects on patient-centric efficacy measures of treatments for patients with depression, and excessive sleepiness associated with obstructive sleep apnea and narcolepsy NEW...
Radioactive Tracer Market Worth $54.29 Billion by 2030 - Exclusive Report by The Insight Partners
August 16, 2023 08:32 ET
|
The Insight Partners
Pune, India, Aug. 16, 2023 (GLOBE NEWSWIRE) -- A radioactive tracer is a chemical compound in which one or more atoms have been replaced by a radioisotope. Through monitoring its radioactive decay,...